All manuscripts
Publications CAR T Cells γδ T G-Rex®24 Well Plate

IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy

Published Journal OncoImmunology

Share
23 pages IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy — OncoImmunology, 2025

Overview

K562 feeder cells expressing membrane-bound IL-21 preferentially expand Vd1 gamma delta T cells from blood. The cells gain NK activation receptors and kill breast and ovarian tumors, with CAR arming improving efficacy in xenografts. PBMCs were seeded in 24-well G-Rex® plates for expansion.

What this paper found

Co-culture of peripheral blood cells with irradiated K562 feeder cells expressing membrane-bound IL-21 and 100 U/mL IL-2 expands γδ T cells that are mainly Vδ1, and these cells kill ovarian and breast cancer cells. Vδ1 cells rose from a mean 6.14% before expansion to 70.20% after eight weeks, while Vδ2 cells fell to 3.79%. Expanded cells showed a higher activation status, controlled OVCAR8 ovarian tumor growth in NRG mice, and kept nutrient-receptor expression and metabolic function in patient ascites fluid. Electroporation with Cas9 and AAV6 delivery gave a HER2 CAR in 62% of cells, and CAR-armed Vδ1 cells produced the greatest tumor reduction in a SKOV3 xenograft model. Studies used healthy-donor blood and mouse models only.

Note: Tumor efficacy was tested in xenograft models in immunocompromised mice; the authors note that these do not fully recapitulate the human tumor microenvironment and that pharmacokinetics of the expanded cells were not assessed.

Overall, our study demonstrates that K562 mb-IL-21 expanded Vδ1 T cells exhibit broad innate cytotoxicity which can be heightened in an antigen-specific manner with a CAR, while maintaining metabolic fitness in the immunosuppressive TME. — Ana L. Portillo, Misaal Mehboob, Genesis Snyder, Adnan Moinuddin, Tyrah M. Ritchie, Elizabeth Balint, Allyson E. Moore, Mohammadamin Sookhaklari, Jonathan L. Bramson, Dean A. Lee, Meisam Naeimi Kararoudi, Ali A. Ashkar, OncoImmunology

Study details

Authors
Ana L. Portillo, Misaal Mehboob, Genesis Snyder, Adnan Moinuddin, Tyrah M. Ritchie, Elizabeth Balint, Allyson E. Moore, Mohammadamin Sookhaklari, Jonathan L. Bramson, Dean A. Lee, Meisam Naeimi Kararoudi, Ali A. Ashkar
Institution
Department of Medicine, McMaster University, Hamilton, ON, Canada · McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada · Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada · Centre for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA · Centre for Childhood Cancer and Blood Diseases, Nationwide Children’s Hospital, The Ohio State University, Columbus, OH, USA
Journal
OncoImmunology
Year
2025
PMID / PMC
PMID: 40996786 · PMC
G-Rex® model(s)
G-Rex®24 Well Plate
Cell type(s)
CAR T Cells, γδ T
Application area
Solid tumor
Study phase
Preclinical

How G-Rex® was used

A 24-well G-Rex® plate (Wilson Wolf) was used to expand zoledronate-activated Vγ9 Vδ2 T cells from bulk PBMCs as a comparator for the expanded Vδ1 cells. PBMCs were seeded at 2×10^6 cells/cm² with 10 mM zoledronic acid and 4 ng/mL IL-2. After four days, cells were moved into CTS OpTmizer medium with 5% CTS Immune Cell Serum Replacement. A 75% media replacement was done every 3–4 days, with IL-2 every 2–3 days and 5 ng/mL IL-15 from day 7. Cells were harvested on day 14 and depleted of αβ T cells with CD4 and CD8 microbeads.

Explore related

Full citation

Portillo AL, Mehboob M, Snyder G, et al. IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy. Oncoimmunology. 2025;14(1):2562210.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →